Takeda Pharmaceutical Company Limited FY2026 FY Earnings Report

Quick View

Executive Summary

For the fiscal year ended March 2026, Revenue was ¥45057B (YoY -¥758B, -1.7%) with a slight decline, Operating Income was ¥62B (YoY -¥3,364B, -98.2%) with a sharp fall, and Ordinary Income was ¥2,055B (YoY +¥1,189B, +137.3%) with a large increase; however, Net Income attributable to owners of the parent was a loss of ¥-1,524B (YoY -¥2,603B, turned from profit to loss). Operating margin plunged to 0.14% (down -736bp from 7.5% prior year). The swing to a net loss was primarily due to product intangible amortization and impairments of ¥6,335B and other operating expenses of ¥5,590B, together with higher finance costs of ¥3,576B. Ordinary Income improved driven by recognition of financial income of ¥2,112B, but Pre-Tax Income deteriorated to ¥-1,424B, making the deterioration in core profitability apparent. Operating Cash Flow was ample at ¥10,414B, helped by non-cash charges (depreciation and amortization ¥7,211B, impairments ¥1,457B, provisions increase ¥4,161B) and foreign-exchange hedge settlement gains of ¥1,297B, but the large divergence from accounting net loss indicates a high weight of one-off factors.

Drivers of Performance

• Revenue: Revenue was ¥45057B (YoY -¥758B, -1.7%) with a slight decline. Cost of sales was ¥15,716B, resulting in gross profit of ¥29,341B and a high gross margin of 65.1%, indicating product pricing and mix remain resilient. Segment-level disclosure was not provided, but inventory build to ¥13,966B (YoY +¥1,793B, +14.7%) and increased intangible amortization/impairment suggest patent expiries or product life-cycle shifts may underlie the revenue decline. R&D expense remained high at ¥6,759B (15.0% of sales), supporting long-term pipeline investment.

• Profitability: Operating Income fell sharply to ¥62B (YoY -¥3,364B, -98.2%), with operating margin down to 0.14% (from 7.5%, -736bp). SG&A was ¥10,843B (YoY -¥206B, -1.9%), a modest reduction roughly in line with sales decline, but product intangible amortization and impairments of ¥6,335B (almost flat vs. prior ¥6,432B) and a sharp rise in other operating expenses to ¥5,590B (from ¥2,067B, +¥3,522B, +170.4%) severely compressed operating profit. Recognition of financial income of ¥2,112B (from ¥465B, +¥1,646B, +353.7%) lifted Ordinary Income to ¥2,055B (YoY +¥1,189B, +137.3%), but higher finance costs of ¥3,576B (from ¥2,101B, +¥1,476B, +70.3%) worsened Pre-Tax Income to ¥-1,424B (turning from prior year profit of ¥1,751B). After corporate income tax expense of ¥98B, Profit for the Period was ¥-1,521B and Net Income attributable to owners of the parent was ¥-1,524B. The large increase in Ordinary Income was driven by volatility in financial gains/losses and FX valuation, not by improvement in core business profitability. Conclusion: slightly lower sales with sharply lower profitability and a turn to a final net loss.

Key Financial Metrics

• Profitability: ROE was -2.1% (from +1.5%, deterioration of -3.6pt), and operating margin was 0.14% (down -736bp from 7.5%), indicating substantial erosion. Net income loss resulted in very low shareholder capital efficiency. Gross margin of 65.1% remained high, but intangible amortization/impairment and increased provisions offset operating leverage. EBIT was ¥211B, and ROA (on Ordinary Income basis) was -1.0%, showing asset efficiency deterioration.

• Cash Quality: Operating Cash Flow was ¥10,414B (YoY -¥160B, -1.5%) and stable. The ratio of operating cash flow to Net Income is -6.83x, reflecting large non-cash and one-off items including depreciation and amortization ¥7,211B, impairments ¥1,457B, provisions increase ¥4,161B, and FX hedge settlement gains ¥1,297B. Accrual ratio is -7.7%, superficially favorable but the high weight of one-off items warrants caution on earnings quality.

• Investment Efficiency: R&D expense ¥6,759B (15.0% of sales) remains within industry norms and pipeline investment continues. Capex was ¥1,760B (3.9% of sales), with tangible fixed assets increasing by ¥1,524B reflecting continued production and site investment. Intangible assets acquired ¥2,349B and licenses ¥37B were recorded.

• Financial Soundness: Equity Ratio was 47.9% (from 48.7%, -0.8pt), and debt-to-equity (debt-equity multiple) was 1.09x, indicating relatively high leverage. Long-term borrowings increased to ¥43697B (YoY +¥4,034B, +10.2%), making interest burden evident. Current ratio was about 109% (Current assets ¥30,905B / Current liabilities ¥28,321B), indicating a thin liquidity cushion. Goodwill of ¥58090B (78.2% of equity, 37.4% of total assets) and intangible assets of ¥34193B remain high and embed future impairment risk.

Cash Flow Analysis

Operating Cash Flow was ¥10,414B (YoY -¥160B, -1.5%) and ample. The large divergence from accounting profit for the period of ¥-1,521B (ratio -6.83x) was driven by non-cash and one-off items including depreciation and amortization ¥7,211B, impairments ¥1,457B, provisions increase ¥4,161B, and FX hedge settlement gains ¥1,297B. Working capital movements included an increase in trade receivables of ¥701B and inventory increase of ¥612B as negatives, while provisions increase of ¥4,161B was a positive contributor. Corporate tax payments were ¥1,804B. Investing Cash Flow was ¥-3,691B, reflecting capex ¥1,760B, intangible asset acquisitions ¥2,349B, and proceeds from business dispositions of ¥333B. Free Cash Flow was ¥6,723B (Operating CF + Investing CF), covering dividends of ¥3,119B by 2.15x and covering dividends + capex total of ¥4,879B by 1.38x. Financing Cash Flow was ¥-4,968B, including long-term borrowings and bond issuances ¥5,861B, repayments ¥2,004B, net decrease in short-term borrowings ¥3,418B, dividend payments ¥3,119B, and share buybacks ¥516B. Cash and cash equivalents rose to ¥5,951B (YoY +¥2,099B, +54.5%), improving liquidity. Inventory days outstanding remained high at 324 days, leaving substantial room to improve working capital efficiency.

Earnings Quality

Recurring earnings are built on pharmaceutical gross profit of ¥29,341B, but this year product intangible amortization and impairments of ¥6,335B and sharply higher other operating expenses of ¥5,590B (YoY +¥3,522B) compressed Operating Income to ¥62B and materially impaired earnings quality. Financial income ¥2,112B (including FX gains and valuation gains) and financial expenses ¥3,576B resulted in a net finance expense of ¥-1,464B, roughly a 3.2% negative impact on sales. The gap between Ordinary Income ¥2,055B and Net Income ¥-1,524B is ¥3,579B, reflecting the large influence of financial results, tax effects, and valuation differences; thereby EBITDA-based measures (EBIT ¥211B + depreciation & amortization ¥7,211B ≈ ¥7,422B) are more appropriate to assess core performance. The structure in which Operating CF substantially exceeds Net Income is mainly due to non-cash and one-off items (depreciation/amortization, impairments, provisions increase, FX hedge settlement gains), and while the accrual ratio of -7.7% appears favorable, the persistence of the provisions increase of ¥4,161B and reproducibility of FX hedge settlement gains ¥1,297B are uncertain. Sustainable core operating income will depend on the lapse of one-off costs and normalization of finance costs.

Forecasts & Guidance

Full-year guidance expects Revenue ¥46400B (vs current period +¥1,343B, +2.9%), Operating Income ¥4,200B (vs current period +¥4,138B, operating margin 9.1%), and Net Income attributable to owners of the parent ¥1,660B (EPS ¥104.26), with a dividend guidance of ¥102 per share, implying a V-shaped recovery. The current period was materially impaired by elevated intangible amortization/impairment, other operating expenses, and higher finance costs, so achieving guidance assumes: (1) a significant reduction/normalization of other operating expenses (from ¥5,590B this period back to the prior-year ¥2,000B-range), (2) suppression of finance costs or realization of hedge benefits, and (3) inventory optimization and working capital improvement. The dividend guidance of ¥102 per share is a cut from the current period’s ¥200 per share, reflecting a conservative stance given profit uncertainty. Progress toward the operating income guidance of ¥4,200B is only 1.5% based on current period results, so expense normalization and revenue improvement are key to achieving guidance.

Shareholder Returns

The current period dividend was interim ¥100 and year-end ¥100, totaling ¥200 per share and total dividends of ¥3,119B (almost unchanged from prior ¥3,103B). Reported payout ratio is not meaningful given Net Income attributable to owners of the parent ¥-1,524B, but the reported 2.9% payout is likely based on management’s internal metric (core profits, etc.). Free Cash Flow of ¥6,723B covers dividends by 2.15x and covers dividends + capex total ¥4,879B by 1.38x. Total shareholder returns including share buybacks ¥516B amounted to ¥3,635B (Total Return Ratio cannot be calculated on an accounting basis). Nonetheless, given rising interest burden (finance costs ¥3,576B), high inventory DIO of 324 days, and goodwill/equity ratio of 78.2% implying latent impairment risk, medium-term sustainability depends on stabilizing cash generation (recovery of core EBITDA) and managing debt costs. The full-year dividend guidance of ¥102 per share is a ¥98 reduction from ¥200 per share in the current period, indicating a shift to a more conservative capital allocation stance.

Risk Factors

1. Intangible asset and goodwill impairment risk: High goodwill of ¥58090B (78.2% of equity, 37.4% of total assets) and intangible assets of ¥34193B persist. This period recognized intangible amortization/impairment of ¥6,335B; future product mix deterioration or patent expiries could trigger additional impairments. Impairment risk greatly exceeds retained earnings of ¥7,124B (9.6% of equity), leaving limited buffer before equity erosion.

2. Interest burden and liquidity risk: Increase in long-term borrowings to ¥43697B (YoY +¥4,034B) has made finance costs of ¥3,576B a burden. Current ratio ~109% is thin, limiting the cushion against maturity mismatches on current liabilities of ¥28,321B. In a rising interest rate environment, interest payments remain a persistent headwind and refinancing conditions could deteriorate. The interest burden relative to EBIT ¥211B has worsened significantly, leaving limited capacity to service interest until profits recover.

3. Inventory valuation and working capital risk: Inventory at ¥13,966B (YoY +¥1,793B, +14.7%) and DIO at 324 days remain elevated. Inventory buildup amid slightly declining sales suggests stagnation and obsolescence risk, increasing chances of valuation losses or higher storage costs. Deterioration in working capital efficiency could pressure the sustainability of Operating Cash Flow and delay improvement in financial flexibility.

Industry Benchmark (Reference — Company Analysis)

Profitability & Return

ROE, operating margin, and net margin all materially exceed the industry medians, placing the company relatively well within the peer set. However, absolute values are still negative or very low, and the company lags major peers.

Growth & Capital Efficiency

Revenue growth trails the industry median by -1.1pt, indicating revenue contraction within the sector. This suggests potential impacts from product life-cycle changes and patent expiries.

※ Source: Company compilation

Earnings Highlights / Points of Attention

1. The swing to a net loss this period was mainly driven by intangible amortization and impairment of ¥6,335B, a sharp rise in other operating expenses of ¥5,590B, and finance costs of ¥3,576B — indicating a large weight of one-off factors. Operating Cash Flow of ¥10,414B is ample and supported by non-cash and one-off items (depreciation/amortization, impairments, provisions increase, FX hedge settlement gains), but the sustainability of cash generation depends on recovery of core EBITDA (i.e., cessation of one-off charges and normalization of finance costs). The guidance assumes Operating Income of ¥4,200B and a V-shaped recovery, but this depends on large reductions in other operating expenses and suppression of finance costs.

2. High goodwill of ¥58090B (78.2% of equity) and intangible assets of ¥34193B remain elevated, making the company sensitive to impairment risk. Elevated inventory DIO of 324 days and a thin current ratio (~109%) indicate working capital and liquidity challenges. The increase in long-term borrowings (+¥4,034B) has made finance costs more evident, placing ROIC and ROE in the lower ranks versus industry benchmarks. Medium-term improvement in capital efficiency will require inventory optimization, selective intangible asset recognition and impairment management, and reduction of interest cost (deleveraging and hedging strategies).

---

This report was automatically generated by AI analyzing XBRL financial statement data. It is not a recommendation to invest in any particular security. Industry benchmarks are compiled by the firm from public financial statements as reference information. Investment decisions are your responsibility; consult a professional advisor as needed.